Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides - Wikidata - thesis-toulmin - TriplyDB

Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides

Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides

http://www.wikidata.org/entity/Q34128861

about

Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System Characterization of transferrin receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin from rice (Oryza sativa L.).Engineering superactive granulocyte macrophage colony-stimulating factor transferrin fusion proteins as orally-delivered candidate agents for treating neurodegenerative disease.Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.SLC39A8 Deficiency: A Disorder of Manganese Transport and Glycosylation.Pharmacokinetics of recombinant bifunctional fusion proteins.Functionalized Graphene Oxide with Chitosan for Protein Nanocarriers to Protect against Enzymatic Cleavage and Retain Collagenase Activity.Proinsulin-transferrin fusion protein as a novel long-acting insulin analog for the inhibition of hepatic glucose production.Fusion protein linkers: property, design and functionality.Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins.Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells.Half-life extended biotherapeutics.Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes Improving the anti-diabetic activity of GLP-1 by fusion with globular adiponectin.A fusion protein derived from plants holds promising potential as a new oral therapy for type 2 diabetes.Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli.Huntington's Disease and Diabetes: Chronological Sequence of its Association.

P2860

Q24562763-7C0ACE66-65B2-4E5D-9DE4-7D195500A457 Q26801319-8938B810-9546-4C85-843A-5DD304206CE1 Q26999386-7090B204-85AE-49C2-B6F2-CB0996860D46 Q34495547-31F35FB0-7090-42EE-A53F-8A9E24DF9DC9 Q35571088-6957711A-4776-42A5-A126-27CFDA98CB01 Q36234711-9FCD6B3A-C0F4-4BB4-BBC3-FDEEB4FB9A00 Q36369946-B24C3E64-B040-4CA8-BA10-1195361D759D Q37033032-27866E32-74FC-4945-9252-812B4A4A2ED4 Q37635372-2EB2B7FF-7145-4795-9CED-DD24C6E2F67A Q37715598-5CBAC900-81B3-4E33-93E4-EA0C98D586D3 Q38048516-EC51DBEC-9752-4442-9ACF-52125FF28AC8 Q38652655-8E32BAF9-36E7-459F-ADED-9B718A465E75 Q38746305-98042B63-C0F5-4E9A-A6AF-1481881C4171 Q38770067-C6FF130E-60E4-4326-8FDA-A8CEA5FEA3B0 Q39066626-62EE3074-FAA6-4232-A213-03AEF78A5F2B Q39569931-CA856462-1B6B-46F2-AC13-7069524BC259 Q43499161-6C52B481-D52D-414A-83F0-AE6C49C37581 Q45330895-04C6B707-D76D-4ABB-AA7B-D516F091E539 Q45811505-F0243987-606E-4ED7-9774-6B3BFDB2A0E7

P2860

Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides

http://www.wikidata.org/entity/Q34128861

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Transferrin fusion technology: ...... ife of insulinotropic peptides

@ast

Transferrin fusion technology: ...... ife of insulinotropic peptides

@en

Transferrin fusion technology: ...... ife of insulinotropic peptides

@nl

type

label

Transferrin fusion technology: ...... ife of insulinotropic peptides

@ast

Transferrin fusion technology: ...... ife of insulinotropic peptides

@en

Transferrin fusion technology: ...... ife of insulinotropic peptides

@nl

prefLabel

Transferrin fusion technology: ...... ife of insulinotropic peptides

@ast

Transferrin fusion technology: ...... ife of insulinotropic peptides

@en

Transferrin fusion technology: ...... ife of insulinotropic peptides

@nl

P1433

Q34128861-9891E609-4CE2-4C8C-AEA4-F3FF18329252

P1476

Q34128861-EB410C63-40D7-4D21-99B1-E7E16C5C3CB4

P2093

Q34128861-0002AF8F-74E5-4F56-A80D-FEF836DB2FAC

Q34128861-61EB69AF-6755-4D88-A66C-0D1F061F94AA

Q34128861-7F125D2C-838C-4118-A4AF-FB46E911073C

Q34128861-84CC049F-E6A4-48E3-BC19-FC3F46AFC391

Q34128861-89D29245-F012-49CC-95C5-26C7744772F1

Q34128861-BE0E5B98-4059-4AB7-A66B-7466F4BA507B

Q34128861-F01BB44A-39C9-44D5-884B-5D385347045D

Q34128861-F0D8D716-2CC0-48B9-B98A-E9C537384090

Q34128861-F250FC16-EF2F-4B43-9FC4-9D83A22CD168

Q34128861-FAF464B6-55C1-4593-9110-EFDE4EEF65BD

P2860

Q34128861-0C8C86D2-DA5E-46C0-BC69-4799E093B9EC

Q34128861-136BDB1A-DDBA-4FE6-B7A1-D9475C4A85AD

Q34128861-150E7497-2CB3-4066-9A64-DB1B9E5B22A9

Q34128861-16DAE8A4-6531-4206-83A6-5BAC6414D920

Q34128861-1F506D37-1E7E-485E-82D6-58EDBAFFDADE

Q34128861-25BBC186-6D1C-48C8-9B5E-ABA6134EC431

Q34128861-2D19A596-3C6E-4261-94CF-F4F12053FC02

Q34128861-3138F750-459D-4920-BAEC-DC520C224324

Q34128861-62DA8927-5B86-4400-939B-3C8C02CF3063

Q34128861-63A0CF13-F5F7-4988-9F2D-9CB47CBD88B3

P304

Q34128861-5A6BD1C1-7D0D-47B0-9F14-3D19753BE417

P31

Q34128861-5B0E0554-35FD-4ED2-8581-E91E72B87BE3

P356

Q34128861-1032ADAE-AD4A-42F0-A5B1-53839E10B453

P407

Q34128861-4CB6A3CA-ED44-4A49-8FED-80441542973A

P433

Q34128861-D161BE74-0361-4BD9-8F9C-7F8BE6E87797

P478

Q34128861-1F99EF72-7802-4635-A97F-FE6BE88E3EB3

P50

Q34128861-2FF1E239-C3F1-478E-A44F-BE0A8D6C5352

Q34128861-94A9ED32-4C37-45B5-BA1E-2394372D3F91

P577

Q34128861-5475563F-B817-4C5E-9ABA-E8B1C2593122

P5875

Q34128861-3DDFB1C1-B802-4FD9-A2D2-9F7733B22B17

P698

Q34128861-53082D7C-D93A-4465-8A5C-233516D40376

P932

Q34128861-3D1095E1-0B28-48AD-9039-9A4192415A7B

P356

JPET.110.166470

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Transferrin fusion technology: ...... ife of insulinotropic peptides

@en

P2093

Andrew Turner

http://www.w3.org/2001/XMLSchema#string

Bronwen Martin

http://www.w3.org/2001/XMLSchema#string

Byung-Joon Kim

http://www.w3.org/2001/XMLSchema#string

Ellen E Ladenheim

http://www.w3.org/2001/XMLSchema#string

Homayoun Sadeghi

http://www.w3.org/2001/XMLSchema#string

Jay Wustner

http://www.w3.org/2001/XMLSchema#string

Jie Zhou

http://www.w3.org/2001/XMLSchema#string

Nigel H Greig

http://www.w3.org/2001/XMLSchema#string

Olga D Carlson

http://www.w3.org/2001/XMLSchema#string

Stuart Maudsley

http://www.w3.org/2001/XMLSchema#string

P2860

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease

Central neurocircuitry associated with emesis

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies

Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury.

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

Transferrin/transferrin receptor-mediated drug delivery.

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

P304

682-692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.110.166470

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

334

http://www.w3.org/2001/XMLSchema#string

P50

Josephine M Egan

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44626291

http://www.w3.org/2001/XMLSchema#string

P698

20498254

http://www.w3.org/2001/XMLSchema#string

P932

2939671

http://www.w3.org/2001/XMLSchema#string